BR112017017115A2 - uso de agente antipatogênico, uso de agente que regula de forma descendente um polipeptídeo associado à matriz extracelular, método para tratamento ou prevenção de doença associada a infecção secundária em um indivíduo infectado com um patógeno, método para tratamento de indivíduo infectado com um patógeno, artigo de fabricação ou composição farmacêutica, e método para tratamento da gripe - Google Patents

uso de agente antipatogênico, uso de agente que regula de forma descendente um polipeptídeo associado à matriz extracelular, método para tratamento ou prevenção de doença associada a infecção secundária em um indivíduo infectado com um patógeno, método para tratamento de indivíduo infectado com um patógeno, artigo de fabricação ou composição farmacêutica, e método para tratamento da gripe

Info

Publication number
BR112017017115A2
BR112017017115A2 BR112017017115-5A BR112017017115A BR112017017115A2 BR 112017017115 A2 BR112017017115 A2 BR 112017017115A2 BR 112017017115 A BR112017017115 A BR 112017017115A BR 112017017115 A2 BR112017017115 A2 BR 112017017115A2
Authority
BR
Brazil
Prior art keywords
treating
pathogen
infected person
agent
extracellular matrix
Prior art date
Application number
BR112017017115-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Sagi Irit
Talmi-Frank Dalit
SOLOMONOV Inna
Amit Ido
Original Assignee
Yeda Research And Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research And Development Co Ltd filed Critical Yeda Research And Development Co Ltd
Publication of BR112017017115A2 publication Critical patent/BR112017017115A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BR112017017115-5A 2015-02-09 2016-02-09 uso de agente antipatogênico, uso de agente que regula de forma descendente um polipeptídeo associado à matriz extracelular, método para tratamento ou prevenção de doença associada a infecção secundária em um indivíduo infectado com um patógeno, método para tratamento de indivíduo infectado com um patógeno, artigo de fabricação ou composição farmacêutica, e método para tratamento da gripe BR112017017115A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562113551P 2015-02-09 2015-02-09
US62/113,551 2015-02-09
PCT/IL2016/050156 WO2016128975A1 (en) 2015-02-09 2016-02-09 Methods of preventing secondary infections

Publications (1)

Publication Number Publication Date
BR112017017115A2 true BR112017017115A2 (pt) 2018-04-03

Family

ID=56615084

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017017115-5A BR112017017115A2 (pt) 2015-02-09 2016-02-09 uso de agente antipatogênico, uso de agente que regula de forma descendente um polipeptídeo associado à matriz extracelular, método para tratamento ou prevenção de doença associada a infecção secundária em um indivíduo infectado com um patógeno, método para tratamento de indivíduo infectado com um patógeno, artigo de fabricação ou composição farmacêutica, e método para tratamento da gripe

Country Status (7)

Country Link
US (2) US10610588B2 (enExample)
EP (1) EP3256135A4 (enExample)
JP (2) JP6783777B2 (enExample)
BR (1) BR112017017115A2 (enExample)
CA (1) CA2974925C (enExample)
HK (1) HK1244667A1 (enExample)
WO (1) WO2016128975A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2974925C (en) 2015-02-09 2022-03-22 Yeda Research And Development Co. Ltd. Methods of preventing secondary infections
USD841023S1 (en) * 2017-08-24 2019-02-19 Domo, Inc. Display screen or portion thereof with a graphical user interface
JP2023530997A (ja) * 2020-06-19 2023-07-20 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｂｓｔ２ロングアイソフォームを標的化する抗ｂｓｔ２抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458777B1 (en) * 1998-03-13 2002-10-01 Mucosal Therapeutics Llc Methods and compositions for treating and preventing mucositis
WO2004064728A2 (en) 2003-01-16 2004-08-05 Paratek Pharmaceuticals, Inc. Use of specific tetracycline compounds in therapy
EP1624866A2 (en) 2003-05-16 2006-02-15 Arriva Pharmaceuticals, Inc. Treatment of respiratory disease by inhalation of synthetic matrix metalloprotease inhibitors
US7910620B2 (en) * 2005-04-22 2011-03-22 Broadhurst Iii Jack J Uses of neuraminidase inhibitors in infectious diseases
WO2015031654A2 (en) * 2013-08-28 2015-03-05 Cytonics Corporation Systems, compositions, and methods for transplantation and treating conditions
CA2974925C (en) 2015-02-09 2022-03-22 Yeda Research And Development Co. Ltd. Methods of preventing secondary infections

Also Published As

Publication number Publication date
US20180028650A1 (en) 2018-02-01
HK1244667A1 (zh) 2018-08-17
EP3256135A4 (en) 2018-06-27
JP2018507847A (ja) 2018-03-22
WO2016128975A1 (en) 2016-08-18
JP7109515B2 (ja) 2022-07-29
JP2021020936A (ja) 2021-02-18
CA2974925C (en) 2022-03-22
US20200261577A1 (en) 2020-08-20
US11400156B2 (en) 2022-08-02
JP6783777B2 (ja) 2020-11-11
EP3256135A1 (en) 2017-12-20
CA2974925A1 (en) 2016-08-18
US10610588B2 (en) 2020-04-07

Similar Documents

Publication Publication Date Title
BR112018003984A2 (pt) anticorpos
MX2015016627A (es) Vacuna para la malaria.
BR112012022797A2 (pt) composição farmacêutica resistente a álcool, e, método para tratar uma doença com uma formulação de agente ativo resistente a álcool
BR112018003985A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
BR112017026467A2 (pt) uso de exossomos para o tratamento de doença
BR112015030389A2 (pt) uso de i) uma fonte de proteína, ii) um prebiótico e iii) um probiótico para a fabricação de uma composição nutricional para o tratamento ou a prevenção de infecção em um indivíduo alérgico
CL2016002794A1 (es) Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico
BR112018077457A2 (pt) composição farmacêutica para evitar ou tratar hiperinsulinismo congênito e seu método, hipoglicemia e seu método, síndrome metabólica e seu método e peptídeo isolado
BR112019011702A2 (pt) tratamento de uma doença do trato gastrointestinal com um inibidor de il-12/il-23 liberado usando um dispositivo ingerível
BR112015011403A2 (pt) uso de akkermansia para o tratamento de distúrbios metabólicos
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
BR112016004305A2 (pt) métodos diagnósticos e composições para tratamento de glioblastoma
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
BR112015021371A2 (pt) uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares
BR112017026746A2 (pt) composições de liberação de fármacos implantáveis e métodos de uso dos mesmos
MX2019003703A (es) Método seguro y eficaz para tratar la psoriasis con el anticuerpo específico anti-il23.
TN2015000402A1 (fr) Methods for treating crohn's disease using an anti-il23 antibody
BR112015017451A2 (pt) formulações farmacêuticas resistentes à violação
BR112017004153A2 (pt) métodos para tratamento de infecções por protozoários
BR112017028137A2 (pt) agente terapêutico para fibrose
BR112013009255A2 (pt) forma de dosagem oral de dissolução rápida de vacina que usa amido
BR112014011896A2 (pt) agentes de rnai, composições e métodos de uso destes para o tratamento de doenças associadas à transtirretina (ttr)
CL2011003327A1 (es) Composicion farmaceutica que comprende finafloxacina y un agente antiinflamatorio; uso en el tratamiento de infecciones oftalmicas, oticas o nasales.
BR112015001521A2 (pt) previsão de resposta ao tratamento para inibidor jak/stat
EP3435979C0 (fr) Composition, notamment composition pharmaceutique préventive et curative, à base de peroxométallate

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]